The role of selenoproteins in cancer;O papel das selenoproteínas no câncer

Revista da Associacao Medica Brasileira

Volumn 56, Issue 4, 2010, Pages 484-488

  de Sousa Almondes, Kaluce Gonçalves ^a   da Silva Leal, Greisse Viero ^a   Cozzolino, Silvia Maria Franciscato ^a   Philippi, Sonia Tucunduva ^a   de Carvalho Rondó, Patrícia Helen ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Neoplasms; Oxidative stress; Selenium; Selenoproteins; Supplementary feeding

Indexed keywords

EID: 77957747514     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0104-42302010000400025     Document Type: Review

References (71)

1. Cutler RG. Oxidative stress profiling: part I. Its potential importance in the optimization of human health. Ann N Y Acad Sci. 2005;1055:93-135.
2. Trueba GP, Sanchez GM, Giuliani A. Oxygen free radical and antioxidant defense mechanism in cancer. Front Biosci. 2004;9:2029-44.
3. Schrauzer GN. Anticarcinogenic effects of selenium. Cell Mol Life Sci. 2000;57:1864-73.
4. Rayman MP. Selenium in cancer prevention: a review of the evidence and mechanism of action. Proc Nutr Soc. 2005;64:527-42.
5. Naithani R. Organoselenium compounds in cancer chemoprevention. Mini Rev Med Chem. 2008;8:657-68.
6. Kim YS, Milner J. Molecular targets for selenium in cancer prevention. Nutr Cancer. 2001;40:50-4.
7. Suzuki KT. Metabolomics of selenium: Se metabolites based on speciation studies. J Sci. 2005;51:107-44.
8. Schrauzer GN. Selenomethionine: a review of its nutritional significance, metabolism and toxicity. J Nutr. 2000;130:1653-6.
9. Steinbrenner H, Sies H. Protection against reactive oxygen species by selenoproteins. Biochim Biophys Acta. 2009;1790:1478-85.
10. Ottaviano FG, Handy DE, Loscalzo J. Redox regulation in the extracellular environment. Circ J. 2008;72:1-16.
11. Maiorino M, Aumann KD, Brigelius-Flohé R, Doria D, Van den Heuvel J, McCarthy J, et al. Probing the presumed catalytic triad of selenium-containing peroxidases by mutational analysis of phospholipid hydroperoxide glutathione peroxidase (PHGPx). Biol Chem Hoppe Seyler. 1995;376:651-60.
12. Brigelius-Flohé R. Tissue-specific functions of individual glutathione peroxidases. Free Radic Biol Med. 1999;27:951-65.
13. Björnstedt M, Hamberg M, Kumar S, Xue J, Holmgren A. Human thioredoxin reductase directly reduces lipid hydroperoxides by NADPH and selenocystine strongly stimulates the reaction via catalytically generated selenols. J Biol Chem. 1995;270:11761-4.
14. Gromadzinska J, Reszka E, Bruzelius K, Wasowicz W, Akesson B. Selenium and cancer: biomarkers of selenium status and molecular action of selenium supplements. Eur J Nutr. 2008;47 (Suppl 2):29-50.
15. Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal. 2007;9:775-806.
16. Gladyshev VN, Jeang KT, Stadtman TC. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc Natl Acad Sci USA. 1996;93:6146-51.
17. Rubartelli A, Bajetto A, Allavena G, Wollman E, Sitia R. Secretion of thioredoxin by normal and neoplastic cells through a leaderless secretory pathway. J Biol Chem. 1992;267:24161-4.
18. Rhee SG, Chae HZ, Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic Biol Med. 2005;38:1543-52.
19. Moskovitz J, Singh VK, Requena J, Wilkinson BJ, Jayaswal RK, Stadtman ER. Purification and characterization ofmethionine sulfoxide reductases from mouse and Staphylococcus aureus and their substrate stereospecificity. Biochem Biophys Res Commun. 2002;290:62-5.
20. Arnér ES, Holmgren, A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem. 2000; 267:6102-9.
21. Jones DP, Carlson JL, Mody VC, Cai J, Lynn MJ, Sternberg P. Redox state of glutathione in human plasma. Free Radic Biol Med. 2000;28:625-35.
22. Björnstedt M, Xue J, Huang W, Akesson B, Holmgren A. The thioredoxin and glutaredoxin systems are efficient electron donors to human plasma glutathione peroxidase. J Biol Chem. 1994;269:29382-4.
23. Akesson B, Bellew T, Burk RF. Purification of selenoprotein P from human plasma. Biochim Biophys Acta. 1994;1204 243-9.
24. Burk RF, Hill KE, Motley AK. Selenoprotein metabolism and function: evidence for more than one function for selenoprotein P. J Nutr. 2003;133(Suppl 1):1517S-20S.
25. Arteel GE, Mostert V, Oubrahim H, Briviba K, Abel J, Sies H. Protection by SeP in human plasma against peroxynitrite-mediated oxidation and nitration. J Biol Chem. 1998;379:1201-5.
26. Saito Y, Hayashi T, Tanaka A, Watanabe Y, Suzuki M, Saito E, et al. Selenoprotein P in human plasma as an extracellular phospholipid hydroperoxide glutathione peroxidase. Isolation and enzymatic characterization of human selenoprotein P. J Biol Chem. 1999;274:2866-71.
27. Suzuki KT, Sasakura C, Yoneda S. Binding sites for the (Hg-Se) complex on selenoprotein P. Biochem Biophys Acta. 1998;1429:102-12.
28. Yan J, Barrett JN. Purification from bovine serum of a survival-promoting factor for cultured central neurons and its identification as selenoprotein-P. J Neurosci. 1998;18:8682-91.
29. Takebe G, Yarimizu J, Saito Y, Hayashi T, Nakamura H, Yodoi J, et al. A comparative study on the hydroperoxide and thiol specificity of the glutathione peroxidase family and selenoprotein P. J Biol Chem. 2002;277:41254-8.
30. Traulsen H, Steinbrenner H, Buchczyk DP, Klotz LO, Sies H, Selenoprotein P protects low-density lipoprotein against oxidation. Free Radic Res. 2004;38:123-8.
31. Steinbrenner H, Alili L, Bilgic E, Sies H, Brenneisen P. Involvement of selenoprotein P in protection of human astrocytes from oxidative damage. Free Radic Biol Med. 2006; 40:1513-23.
32. Steinbrenner H, Bilgic E, Alili L, Sies H, Brenneisen P. Selenoprotein P protects endothelial cells from oxidative damage by stimulation of glutathione peroxidase expression and activity. Free Radic Res. 2006;40:936-43.
33. Ratnasinghe D, Tangrea JA, Andersen MR, Barrett MJ, Virtamo J, Taylor PR, et al. Glutathione peroxidase codon 198 polymorphism variant increases lung cancer risk. Cancer Res. 2000;60:6381-3.
34. Moscow JA, Schmidt L, Ingram DT, Gnarra J, Johnson B, Cowan KH. Loss of heterozygosity of the human cytosolic glutathione peroxidase I gene in lung cancer. Carcinogenesis. 1994;15:2769-73.
35. Al-Taie OH, Uceyler N, Eubner U, Jakob F, Mörk H, Scheurlen M, et al. Expression profiling and genetic alterations of the selenoproteins GI-GPx and SePP in colorectal carcinogenesis. Nutr Cancer. 2004;48:6-14.
36. Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, et al. Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res. 2002;62:5325-35.
37. Murawaki Y, Tsuchiya H, Kanbe T, Harada K, Yashima K, Nozaka K, et al. Aberrant expression of selenoproteins in the progression of colorectal cancer. Cancer Lett. 2008;259:218-30.
38. Urig S, Becker K. On the potential of thioredoxin reductase inhibitors for cancer therapy. Semin Cancer Biol. 2006;16:452-65.
39. Diwadkar-Navsariwala V, Prins GS, Swanson SM, Birch LA, Ray VH, Hedayat S, et al. Selenoprotein deficiency accelerates prostate carcinogenesis in a transgenic model. Proc Natl Acad Sci USA. 2006;23:8179-84.
40. Waters DJ, Shen S, Glickman LT, Cooley DM, Bostwick DG, Qian J, et al. Prostate cancer risk and DNA damage: translational significance of selenium supplementation in a canine model. Carcinogenesis. 2005;26:1256-62.
41. Baliga MS, Wang H, Zhuo P, Schwartz JL, Diamond AM. Selenium and GPx-1 overexpression protect mammalian cells against UV-induced DNA damage. Biol Trace Elem Res. 2007;115:227-42.
42. Heirman I, Ginneberge D, Brigelius-Flohé R, Hendrickx N, Agostinis P, Brouckaert P, et al. Blocking tumor cell eicosanoid synthesis by GPx 4 impedes tumor growth and malignancy. Free Radic Biol Med. 2006;40:285-94.
43. Banning A, Kipp A, Schmitmeier S, Löwinger M, Florian S, Krehl S, et al. Glutathione peroxidase 2 inhibits cyclooxygenase-2-mediated migration and invasion of HT-29 adenocarcinoma cells but supports their growth as tumors in nude mice. Cancer Res. 2008;68:9746-53.
44. Yoo MH, Xu XM, Carlson BA, Gladyshev VN, Hatfield DL. Thioredoxin reductase 1 deficiency reverses tumor phenotype and tumorigenicity of lung carcinoma cells. J. Biol Chem. 2006;281:13005-8.
45. Lillig, CH, Holmgren, A. Thioredoxin and related molecules--from biology to health and disease. Antioxid Redox Signal. 2007;9:25-47.
46. Cassidy PB, Edes K, Nelson CC, Parsawar K, Fitzpatrick FA, Moos PJ.Thioredoxin reductase is required for the inactivation of tumor suppressor p53 and for apoptosis induced by endogenous electrophiles. Carcinogenesis. 2006;27:2538-49.
47. Park JM, Kim A, Oh JH, Chung AS. Methylseleninic acid inhibits PMA-stimulated pro-MMP-2 activationmediated byMT1-MMP expression and further tumor invasion through suppression of NF-kappaB activation. Carcinogenesis. 2007;28:837-47.
48. Gundimeda U, Schiffman JE, Chhabra D, Wong J, Wu A, Gopalakrishna R. Locally generated methylseleninic acid induces specific inactivation of protein kinase C isoenzymes: relevance to selenium-induced apoptosis in prostate cancer cells. J Biol Chem. 2008;283:34519-31.
49. Zeng H, Combs Jr GF. Selenium as an anticancer nutrient: roles in cell proliferation and tumor cell invasion. J Nutr Biochem. 2008;19:1-7.
50. Navarro-Alcaron M, Cabrera-Vique C. Selenium in food and the human body: A review. Sci Total Environ. 2008;400:115-41.
51. Czeczot H, Scibior D, Skrzycki M, Podsiad M. Glutathione and GSH-dependant enzymes in patients with liver cirrhosis and hepatocellular carcinoma. Acta Biochim Pol. 2006;53:237-41.
52. Simonoff M, Simonoff G, editors. Le selenium. Paris: Masson; 1991.
53. Reid ME, Duffield-Lillico AJ, Slate E, Natarajan N, Turnbull B, Jacobs E, et al. The nutritional prevention of cancer: 400 mcg per day selenium treatment. Nutr Cancer. 2008;60:155-63.
54. Clark LC, Combs GF, Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin: a randomized controlled trial: nutritional prevention of cancer study group. JAMA. 1996;276:1957-63.
55. Duffield-Lillico AJ, Reid ME, Turnbull BW, Combs GF Jr, Slate EH, Fischbach LA, et al. Baseline characteristics and the effect of selenium supplementation on cancer incidence in a randomized clinical trial: a summary report of the nutritional prevention of cancer trial. Cancer Epidemiol Biomarkers Prev. 2002;11:630-9.
56. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003;91:608-12.
57. Karunasinghe N, Ferguson LR, Tuckey J, Masters J. Hemolysate thioredoxin reductase and glutathione peroxidase activities correlate with serum selenium in a group of New Zealand men at high prostate cancer risk. J Nutr. 2006;136:2232-35.
58. Romanowska M, Kikawa KD, Fields JR, Maciag A, North SL, Shioa YH, et al. Effects of selenium supplementation on expression of glutathione peroxidase isoforms in cultured human lung adenocarcinoma cell lines. Lung Cancer. 2007;55:35-42.
59. Kocdor H, Cehreli R, Kocdor MA, Sis B, Yilmaz O, Canda T et al. Toxicity induced by the chemical carcinogen 7,12-dimethylbenz[a]anthracene and the protective effects of selenium in Wistar rats. J Toxicol Environ Health A. 2005;68:693-701.
60. Rafferty TS, Walker C, Hunter JA, Beckett GJ, McKenzie RC. Inhibition of ltraviolet B radiation-induced interleukin 10 expression in murine keratinocytes by selenium compounds. Br J Dermatol.2002;146:485-9.
61. Bjorkhem-Bergman L, Torndal UB, Eken S, Nystrom C, Capitanio A, Larsen EH, et al. Selenium prevents tumor development in a rat model for chemical carcinogenesis. Carcinogenesis. 2005;26:125-31.
62. Bardia A, Tleyjeh IM, Cerhan JR, Sood AK, Limburg PJ, Erwin PJ, et al. Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis. Mayo Clin Proc. 2008;83:23-34.
63. Peters U, Takata Y. Selenium and the prevention of prostate and colorectal cancer. Mol Nutr Food Res. 2008;52:1261-72.
64. Nadiminty N, Gao AC. Mechanisms of selenium chemoprevention and therapy in prostate cancer. Mol Nutr Food Res. 2008;52:1247-60.
65. Rudolf E, Králová V, Cervinka M. Selenium and colon cancer--from chemoprevention to new treatment modality. Anticancer Agents Med Chem. 2008;8:598-602.
66. Reid ME, Duffield-Lillico AJ, Sunga A, Fakih M, Alberts DS, Marshall JR. Selenium supplementation and colorectal adenomas: an analysis of the nutritional prevention of cancer trial. Int J Cancer. 2006;118:1777-81.
67. Etminan M, FitzGerald JM, Gleave M, Chambers K. Intake of selenium in the prevention of prostate cancer: a systematic review and meta-analysis. Cancer Causes Control. 2005;16:1125-31.
68. Meuillet E, Stratton S, Cherukuri DP, Goulet AC, Kagey J, Porterfield B, et al. Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings. J Cell Biochem. 2004;91:443-58.
69. Al-Taie OH, Seufert J, Karvar S, Adolph C, Mörk H, Scheurlen M, et al. Selenium supplementation enhances low selelnium levels and stimulates glutathione peroxidase activity in peripheral blood and distal colon mucosa in past and present carriers of colon adenomas. Nutr Cancer. 2003;46:125-30.
70. Brinkman M, Buntinx F, Muls E, Zeegers MP. Use of selenium in chemoprevention of bladder cancer. Lancet Oncol. 2006;7:766-74.
71. Sieja K, Talerczyk M. Selenium as an element in the treatment of ovarian cancer in woman receiving chemotherapy. Gynecol Oncol. 2004;93:320-7.